278 related articles for article (PubMed ID: 26187455)
1. Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.
Ben Hadj Yahia MB; Jouin-Bortolotti A; Dervaux B
Clin Drug Investig; 2015 Aug; 35(8):471-85. PubMed ID: 26187455
[TBL] [Abstract][Full Text] [Related]
2. Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness.
Soe NN; Ong JJ; Ma X; Fairley CK; Latt PM; Jing J; Cheng F; Zhang L
Hum Vaccin Immunother; 2018; 14(12):3010-3018. PubMed ID: 30024823
[TBL] [Abstract][Full Text] [Related]
3. Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men.
Lin A; Ong KJ; Hobbelen P; King E; Mesher D; Edmunds WJ; Sonnenberg P; Gilson R; Bains I; Choi YH; Tanton C; Soldan K; Jit M
Clin Infect Dis; 2017 Mar; 64(5):580-588. PubMed ID: 28011615
[TBL] [Abstract][Full Text] [Related]
4. The cost effectiveness of human papillomavirus vaccines: a systematic review.
Seto K; Marra F; Raymakers A; Marra CA
Drugs; 2012 Mar; 72(5):715-43. PubMed ID: 22413761
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
Li X; Stander MP; Van Kriekinge G; Demarteau N
BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
[TBL] [Abstract][Full Text] [Related]
6. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
7. Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis.
Wahab MT; Tan RKJ; Cook AR; Prem K
Vaccine; 2023 Mar; 41(12):1934-1942. PubMed ID: 36797100
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review.
Mahumud RA; Alam K; Keramat SA; Ormsby GM; Dunn J; Gow J
PLoS One; 2020; 15(6):e0233499. PubMed ID: 32484811
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
10. Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries.
Simonella L; Canfell K
Vaccine; 2015 Jan; 33(1):34-51. PubMed ID: 25171843
[TBL] [Abstract][Full Text] [Related]
11. A targeted literature review of health economic analyses of human papillomavirus vaccination from various countries.
Segal HA; Rashid N
Int J STD AIDS; 2023 Jul; 34(8):512-517. PubMed ID: 36971102
[TBL] [Abstract][Full Text] [Related]
12. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
13. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.
Laprise JF; Drolet M; Boily MC; Jit M; Sauvageau C; Franco EL; Lemieux-Mellouki P; Malagón T; Brisson M
Vaccine; 2014 Oct; 32(44):5845-53. PubMed ID: 25131743
[TBL] [Abstract][Full Text] [Related]
14. Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries.
Kostaras D; Karampli E; Athanasakis K
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):147-158. PubMed ID: 30501434
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
16. [A systematic review in health economics research on the expansion of human papilloma virus vaccination population to men].
Su Y; He HQ; Zhou Y; Deng X
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Nov; 57(11):1869-1877. PubMed ID: 38008579
[No Abstract] [Full Text] [Related]
17. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review.
Harder T; Wichmann O; Klug SJ; van der Sande MAB; Wiese-Posselt M
BMC Med; 2018 Jul; 16(1):110. PubMed ID: 30016957
[TBL] [Abstract][Full Text] [Related]
18. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
19. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
